The non-coding oncofetal H19 gene in brain tumors

Therapeutic Ribonucleic Acids in Brain Tumors

Volumn , Issue , 2009, Pages 471-484

  Fellig, Y ^a   Amit, D ^b   Matouk, I J ^b   Kopolovic, J ^a   Erdmann, V A ^c   Hochberg, A ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84859965052     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-00475-9_21     Document Type: Chapter

References (44)

1. Adriaenssens E, Lottin S, Berteaux N et al (2002) Cross-talk between mesenchyme and epithelium increases H19 gene expression during scattering and morphogenesis of epithelial cells. Exp Cell Res 275:215-229.
2. Albrecht S, Waha A, Koch A et al (1996) Variable imprinting of H19 and IGF2 in fetal cerebellum and medulloblastoma. J Neuropathol Exp Neurol 55:1270-1276.
3. Ayesh S, Matouk I, Schneider T et al (2002) Possible physiological role of H19 RNA. Mol Carcinog 35:63-74.
4. Ayesh B, Matouk I, Ohana P et al (2003) Inhibition of tumor growth by DT-A expressed under the control of IGF2 P3 and P4 promoter sequences. Mol Ther 7:535-541.
5. Barsyte-Lovejoy D, Lau SK, Boutros PC et al (2006) The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. Cancer Res 66:5330-5337.
6. Beier D, Hau P, Proescholdt M et al (2007) CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67:4010-415.
7. Berteaux N, Lottin S, Monte D et al (2005) H19 mRNA-like noncoding RNA promotes breast cancer cell proliferation through positive control by E2F1. J Biol Chem 280:29625-26636.
8. Brannan CI, Dees EC, Ingram RS et al (1990) The product of the H19 gene may function as an RNA. Mol Cell Biol 10:28-36.
9. Cai X, Cullen BR (2007) The imprinted H19 noncoding RNA is a primary microRNA precursor. RNA 13:313-316.
10. Dugimont T, Montpellier C, Adriaenssens E et al (1998) The H19 TATA-less promoter is efficiently repressed by the wild- Type tumor suppressor gene product p53. Oncogene 16:2395-2401.
11. Engebraaten O, Hjortland GO, Juell S et al (2002) Intratumoral Immunotoxin treatment of human malignant brain tumors in immunodeficient animals. Int J Cancer 97:846-852.
12. Ferguson S, Lesniak MS (2007) Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors. Curr Drug Deliv 4:169-180.
13. Freed WJ, Chen J, Bäckman CM et al (2008) Gene expression profile of neuronal progenitor cells derived from hESCs: Activation of chromosome 11p15.5 and comparison to human dopaminergic neurons. PLoS ONE 3(1):e1422.
14. Griguer CE, Oliva CR, Gobin E et al (2008) CD133 is a marker of bioenergetic stress in human glioma. PLoS ONE 3(11):e3655.
15. Hall WA, Sherr GT (2006) Convection-enhanced delivery of targeted toxins for malignant glioma. Expert Opin Drug Deliv 3:371-377.
16. Hao Y, Crenshaw T, Moulton T et al (1993) Tumor-suppressor activity of H19 RNA. Nature 365:764-767.
17. Ioannidis P, Kottaridi C, Dimitriadis E et al (2004) Expression of the RNA-binding protein CRD-BP in brain and non-small cell lung tumors. Cancer Lett 209:245-250.
18. Kim KS, Lee YI (1997) Biallelic expression of the H19 and IGF2 genes in hepatocellular carcinoma. Cancer Lett 119:143-148.
19. Kleihues P, Burger PC, Aldape KD et al (2007) Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds). World Health Organization Classification of Tumours. Pathology and genetics of tumours of the nervous system. Lyon, IARC, pp 33-49.
20. Laske DW, Youle RJ, Oldfield EH (1997) Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3:1362-1368.
21. Leibovitch MP, Nguyen VC, Gross MS et al (1991) The human ASM (adult skeletal muscle) gene: expression and chromosomal assignment to 11p15. Biochem Biophys Res Commun 180:1241-1250.
22. Liu TF, Willingham MC, Tatter SB et al (2003) Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells. Bioconjug Chem 14:1107-1114.
23. Liu TF, Hall PD, Cohen KA et al (2005) Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clin Cancer Res 11:329-334.
24. Lizuka N, Oka M, Yamada-Okabe H et al (2002) Comparison of gene expression profiles between hepatitis B virus- And hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res 62:3939-3944.
25. Lustig O, Ariel I, Ilan J et al (1994) Expression of the imprinted gene H19 in the human fetus. Mol Reprod Dev 38:239-246.
26. Manoharan H, Babcock K, Willi J et al (2003) Biallelic expression of the H19 gene during spontaneous hepatocarcinogenesis in the albumin SV40 T antigen transgenic rat. Mol Carcinog 38:40-47.
27. Martell LA, Agrawal A, Ross DA et al (1993) Efficacy of transferring receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors. Cancer Res 53:1348-1353.
28. Matouk I, Ayesh B, Schneider T et al (2004) Oncofetal splice pattern the human H19 gene. Biochem Biophys Res Commun 318:916-919.
29. Matouk I, Ohana P, Ayesh S et al (2005) The oncofetal H19 RNA in human cancer, from the bench to the patient. Cancer Ther 3:249-266.
30. Matouk I, de Groot N, Mezan S et al (2007) The H19 non-coding RNA is essential for human tumor growth. PloS ONE 2(9):e845.
31. Matouk I, Ohana P, Galun E et al (2008) The pivotal role of the H19 gene in tumor development, a new hope. In: Campbell RN (ed) Gene therapy and cancer research focus. Nova Science Publishers, pp 241-260.
32. Müller S, Zirkel D, Westphal M et al (2000) Genomic imprinting of IGF2 and H19 in human meningiomas. Eur J Cancer 36:651-655.
33. Pachnis V, Brannan CL, Tilghman SM (1988) The structure and expression of a novel gene activated in early mouse embryogenesis. EMBO J 7:673-681.
34. Pham NV, Nguyen MT, Hu JF et al (1998) Dissociation of IGF2 and H19 imprinting in human brain. Brain Res 810:1-8.
35. Poirier F, Chan CT, Timmons PM et al (1991) The murine H19 gene is activated during embryonic stem cell differentiation in vitro at the time of implantation in the developing embryo. Development 113:1105-1114.
36. Rachmilewitz J, Goshen R, Ariel I et al (1992) Parental imprinting of the human H19 gene. FEBS Lett 309:25-28.
37. Rainov NG, Gorbatyuk K, Heidecke V (2008) Clinical trials with intracerebral convectionenhanced delivery of targeted toxins in malignant glioma. Rev Recent Clin Trials 3:2-9.
38. Sidi AA, Ohana P, Benjamin S et al (2008) Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 over expressing superficial bladder cancer refractory to bacillus Calmette-Guerin. J Urol 180:2379-2383.
39. Smits G, Mungall AJ, Griffiths-Jones S et al (2008) Conservation of the H19 noncoding RNA and H19-IGF2 imprinting mechanism in therians. Nat Genet 40:971-976.
40. Tsang WP, Kwok TT (2007) Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. Oncogene 26:4877-4881.
41. Uyeno S, Aoki Y, Nata M et al (1996) IGF2 but not H19 shows loss of imprinting in human glioma. Cancer Res 56:5356-5359.
42. von Deimling A, Burger PC, Nakazato Y et al (2007) Diffuse astrocytomas. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds). World Health Organization Classification of Tumours. Pathology and genetics of tumours of the nervous system. Lyon, IARC, pp 25-29.
43. Weaver M, Laske DW (2003) Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 65:3-13.
44. Zhang Y, Tycko B (1992) Monoallelic expression of the human H19 gene. Nat Genet 1:40-44.